Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.

DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 07; 24(7):1197-1205.

View in: PubMed

collapse authors with profiles